Apyx Medical (APYX) 10-Q 11 Aug 22 2022 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2022	Aug. 10, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	0-12183
Entity Registrant Name	APYX MEDICAL CORPORATION
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	11-2644611
Entity Address, Address Line One	5115 Ulmerton Road,
Entity Address, City or Town	Clearwater
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33760
City Area Code	727
Local Phone Number	384-2323
Title of 12(b) Security	Common Stock
Trading Symbol	APYX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		34,573,034
Entity Central Index Key	0000719135
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 20,063	$ 30,870
Trade accounts receivable, net of allowance of $629 and $430	10,340	13,038
Income tax receivables	7,642	7,642
Other receivables	33	483
Inventories, net of provision for obsolescence of $360 and $263	9,677	6,778
Prepaid expenses and other current assets	2,770	1,926
Total current assets	50,525	60,737
Property and equipment, net of accumulated depreciation and amortization of $5,245 and $5,316	6,842	6,575
Operating lease right-of-use assets	659	121
Finance lease right-of-use assets	176	178
Other assets	1,269	1,110
Total assets	59,471	68,721
Current liabilities:
Accounts payable	2,587	2,631
Accrued expenses and other current liabilities	8,570	10,287
Current portion of operating lease liabilities	110	122
Current portion of finance lease liabilities	85	165
Total current liabilities	11,352	13,205
Long-term operating lease liabilities	514	0
Long-term finance lease liabilities	93	18
Long-term contract liabilities	1,207	1,323
Other liabilities	142	166
Total liabilities	13,308	14,712
EQUITY
Common stock, $0.001 par value; 75,000,000 shares authorized; 34,493,085 issued and outstanding as of June 30, 2022, and 34,409,912 issued and outstanding as of December 31, 2021	34	34
Additional paid-in capital	69,793	66,221
Accumulated deficit	(23,922)	(12,551)
Total stockholders’ equity	45,905	53,704
Non-controlling interest	258	305
Total equity	46,163	54,009
Total liabilities and equity	$ 59,471	$ 68,721

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Allowance for doubtful accounts receivable	$ 629	$ 430
Inventories, provision for obsolescence	360	263
Accumulated depreciation and amortization	$ 5,245	$ 5,316
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	75,000,000	75,000,000
Common stock, shares issued (in shares)	34,493,085	34,409,912
Common stock, shares outstanding (in shares)	34,493,085	34,409,912

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Sales	$ 10,292	$ 11,224	$ 22,785	$ 19,862
Cost of sales	3,378	3,690	7,652	6,468
Gross profit	6,914	7,534	15,133	13,394
Other costs and expenses:
Research and development	1,070	1,084	2,228	2,199
Professional services	2,389	1,889	4,675	3,410
Salaries and related costs	4,892	4,343	10,073	8,588
Selling, general and administrative	4,539	4,261	10,004	7,985
Total other costs and expenses	12,890	11,577	26,980	22,182
Loss from operations	(5,976)	(4,043)	(11,847)	(8,788)
Interest income	18	4	20	7
Interest expense	(3)	(2)	(11)	(6)
Other income, net	607	97	586	4
Total other income, net	622	99	595	5
Loss before income taxes	(5,354)	(3,944)	(11,252)	(8,783)
Income tax expense	96	107	166	173
Net loss	(5,450)	(4,051)	(11,418)	(8,956)
Net loss attributable to non-controlling interest	(24)	(5)	(47)	(9)
Net loss attributable to stockholders	$ (5,426)	$ (4,046)	$ (11,371)	$ (8,947)
Loss per share:
Basic (in dollars per share)	$ (0.16)	$ (0.12)	$ (0.33)	$ (0.26)
Diluted (in dollars per share)	$ (0.16)	$ (0.12)	$ (0.33)	$ (0.26)

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Non-controlling Interest
Beginning balance (in shares) at Dec. 31, 2020		34,289
Beginning balance at Dec. 31, 2020	$ 63,859	$ 34	$ 61,066	$ 2,621	$ 138
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Contributions from non-controlling interest	195				195
Shares issued on stock options exercises for cash (in shares)		8
Shares issued on stock options exercises for cash	21		21
Stock based compensation	2,563		2,563
Shares issued on net settlement of stock options (in shares)		26
Net loss	(8,956)			(8,947)	(9)
Ending balance (in shares) at Jun. 30, 2021		34,323
Ending balance at Jun. 30, 2021	57,682	$ 34	63,650	(6,326)	324
Beginning balance (in shares) at Mar. 31, 2021		34,318
Beginning balance at Mar. 31, 2021	60,169	$ 34	62,281	(2,280)	134
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Contributions from non-controlling interest	195				195
Stock based compensation	1,369		1,369
Shares issued on net settlement of stock options (in shares)		5
Net loss	(4,051)			(4,046)	(5)
Ending balance (in shares) at Jun. 30, 2021		34,323
Ending balance at Jun. 30, 2021	57,682	$ 34	63,650	(6,326)	324
Beginning balance (in shares) at Dec. 31, 2021		34,410
Beginning balance at Dec. 31, 2021	54,009	$ 34	66,221	(12,551)	305
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares issued on stock options exercises for cash (in shares)		44
Shares issued on stock options exercises for cash	208		208
Stock based compensation	3,364		3,364
Shares issued on net settlement of stock options (in shares)		39
Net loss	(11,418)			(11,371)	(47)
Ending balance (in shares) at Jun. 30, 2022		34,493
Ending balance at Jun. 30, 2022	46,163	$ 34	69,793	(23,922)	258
Beginning balance (in shares) at Mar. 31, 2022		34,453
Beginning balance at Mar. 31, 2022	49,843	$ 34	68,023	(18,496)	282
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares issued on stock options exercises for cash (in shares)		20
Shares issued on stock options exercises for cash	56		56
Stock based compensation	1,714		1,714
Shares issued on net settlement of stock options (in shares)		20
Net loss	(5,450)			(5,426)	(24)
Ending balance (in shares) at Jun. 30, 2022		34,493
Ending balance at Jun. 30, 2022	$ 46,163	$ 34	$ 69,793	$ (23,922)	$ 258

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities
Net loss	$ (11,418)	$ (8,956)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	472	440
Provision for inventory obsolescence	139	13
Loss on disposal of property and equipment	47	0
Stock based compensation	3,364	2,563
Provision for allowance for doubtful accounts	284	46
Changes in operating assets and liabilities:
Trade receivables	2,236	(656)
Prepaid expenses and other assets	(549)	(1,160)
Inventories	(3,187)	(1,198)
Accounts payable	33	1,296
Accrued and other liabilities	(1,811)	554
Net cash used in operating activities	(10,390)	(7,058)
Cash flows from investing activities
Purchases of property and equipment	(680)	(221)
Net cash used in investing activities	(680)	(221)
Cash flows from financing activities
Proceeds from stock option exercises	208	21
Repayment of finance lease liabilities	(108)	(120)
Contributions from non-controlling interests	0	195
Net cash provided by financing activities	100	96
Effect of exchange rates on cash	163	(62)
Net change in cash and cash equivalents	(10,807)	(7,245)
Cash and cash equivalents, beginning of period	30,870	41,915
Cash and cash equivalents, end of period	20,063	34,670
Cash paid for:
Interest	11	4
Income taxes	8	13
Non cash activities:
Right-of-use assets capitalized and operating lease liabilities recognized upon lease modification	600	0
Right-of-use assets capitalized and finance lease liabilities recognized upon execution of lease	$ 103	$ 0

BASIS OF PRESENTATION

BASIS OF PRESENTATION	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION Apyx Medical Corporation (“Company”, “Apyx”, “it” and similar terms) was incorporated in 1982, under the laws of the State of Delaware and has its principal executive office at 5115 Ulmerton Road, Clearwater, FL 33760. The Company is an advanced energy technology company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Technology products marketed and sold as Renuvion® in the cosmetic surgery and J-Plasma® in the hospital surgical market. Renuvion® and J-Plasma® offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. On March 14, 2022, the U.S. Food and Drug Administration (“FDA”) posted a Safety Communication that warns consumers and health care providers against the use of the Company’s Advanced Energy products outside of their FDA-cleared indications for general use in cutting, coagulation, and ablation of soft tissue during open and laparoscopic surgical procedures. Following the Safety Communication, the Company experienced slowed demand for the adoption of its Helium Plasma Technology. On May 26, 2022, the Company announced that it had received 510(k) clearance from the FDA for the use of the Renuvion® Dermal Handpiece for specific dermal resurfacing procedures. On July 18, 2022, the Company announced that it had received 510(k) clearance from the FDA for the use of the Renuvion® APR Handpiece for certain skin contraction procedures. Management believes that receiving these clearances should materially mitigate the financial effects of the Safety Communication in future periods. On June 2, 2022, and July 21, 2022, FDA updated the Medical Device Safety Communication to recognize the new 510(k) clearances for the Renuvion® Dermal handpiece, and the expanded indications for the Renuvion® APR handpieces. The 510(k) clearance for the Renuvion® Dermal handpiece allows surgeons to perform dermal resurfacing procedures for the treatment of moderate to severe wrinkles and rhytides, limited to patients with Fitzpatrick Skin Types I, II or III. The 510(k) clearance for the Renuvion® APR handpieces now addresses improving the appearance of lax (loose) skin in the neck and submental region. The accompanying unaudited condensed consolidated financial statements have been prepared based upon SEC rules that permit reduced disclosure for interim periods. For a more complete discussion of significant accounting policies and certain other information, please refer to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021. In the opinion of management these condensed consolidated financial statements reflect all adjustments that are necessary for a fair presentation of results of consolidated operations and financial condition for the interim periods shown, including normal recurring accruals and other items. The results for the interim periods are not necessarily indicative of results for the full year. Reclassifications We have reclassified certain amounts presented in the prior period to conform to the current period presentation. These reclassifications had no impact on previously reported net loss, retained earnings or net cash used in operating activities for the periods presented.

RECENT ACCOUNTING PRONOUNCEMENT

RECENT ACCOUNTING PRONOUNCEMENTS	6 Months Ended
	Jun. 30, 2022
Accounting Standards Update and Change in Accounting Principle [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	RECENT ACCOUNTING PRONOUNCEMENTS In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments—Credit Losses (Topic 326). The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates , which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently expects to continue to qualify as a Smaller Reporting Company, based upon the current SEC definition, and as a result, will be utilizing the deferred elective date. While we are in the process of determining the effects of the adoption of the standard on the condensed consolidated financial statements, we do not expect the impact to be material. No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.

DISPOSAL OF BUSINESS

DISPOSAL OF BUSINESS	6 Months Ended
	Jun. 30, 2022
Discontinued Operations and Disposal Groups [Abstract]
DISPOSAL OF BUSINESS	DISPOSAL OF BUSINESS On August 30, 2018, the Company closed on a definitive asset purchase agreement (the “Asset Purchase Agreement”) with Specialty Surgical Instrumentation Inc., a Tennessee Corporation and wholly owned subsidiary of Symmetry Surgical Inc. (“Symmetry”), pursuant to which the Company divested and sold the Company ’ s electrosurgical “Core” business segment and related intellectual property, including the Bovie® brand and trademarks, to Symmetry for gross proceeds of $97 million in cash. In connection with the Asset Purchase Agreement, the Company entered into an Electro Surgical Disposables and Accessories, Cauteries and Other Products Supply Agreement with Symmetry for a four-year term, whereby it will manufacture certain Core pro ducts and sell them to Symmetry at agreed upon prices. Any activity resulting from this agreement is netted and reported in the Condensed Consolidated Statements of Operations as other income (loss). Core activity for the three months ended June 30, 2022, amounted to $0.0 million with cost of sales equivalents of $0.0 million and other related expenses of $0.1 million for approximately no net other income (loss). Core activity for the three months ended June 30, 2021, amounted to $2.2 million with cost of sales equivalents of $1.8 million and related other expenses of $0.3 million for net other income of $0.1 million. Core activity for the six months ended June 30, 2022 , amounted to $0.6 million with cost of sales equivalents of $0.5 million and other related expenses of $0.1 million for net other loss of $0.1 million. Core activity for the six months ended June 30, 2021 , amounted to $3.6 million with cost of sales equivalents of $3.0 million and net other related operating expenses of $0.6 million for approximately no net other income.

INVENTORIES

INVENTORIES	6 Months Ended
	Jun. 30, 2022
Inventory Disclosure [Abstract]
INVENTORIES	INVENTORIES Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon direct labor hours. Inventories consisted of the following: (In thousands) June 30, December 31, Raw materials $ 4,547 $ 3,603 Work in process 2,192 1,441 Finished goods 3,298 1,997 Gross inventories 10,037 7,041 Less: provision for obsolescence (360) (263) Inventories, net $ 9,677 $ 6,778

LEASES

LEASES	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
LEASES	LEASES Operating Leases The Company leases its facility in Sofia, Bulgaria and vehicles in Clearwater, Florida under non-cancelable operating lease agreements. During the three months ended June 30, 2022, the Company entered into a five year extension of its Sofia, Bulgaria facility. These operating leases have terms expiring through December 2027. Finance Leases The Company has entered into non-cancelable finance leases for certain computer equipment and a vehicle in Clearwater, Florida. During the three months ended June 30, 2022, the Company entered into a 63 month lease for computer equipment. These finance leases have terms expiring through July 2027. Information about the Company’s weighted average remaining lease terms and discount rate assumptions are as follows: June 30, 2022 December 31, 2021 Operating Finance Operating Finance Weighted average remaining lease term (in years) 5.5 3.2 1.0 0.8 Weighted average discount rate 1.83% 3.04% 3.98% 4.00% Maturities of lease liabilities as of June 30, 2022 are as follows: (In thousands) Operating Finance 2022 $ 61 $ 70 2023 119 40 2024 119 21 2025 119 21 2026 119 21 Thereafter 119 12 Total lease payments 656 185 Less imputed interest (32) (7) Present value of lease liabilities 624 178 Less current portion of lease liabilities (110) (85) Long-term portion of lease liabilities $ 514 $ 93
LEASES	LEASES Operating Leases The Company leases its facility in Sofia, Bulgaria and vehicles in Clearwater, Florida under non-cancelable operating lease agreements. During the three months ended June 30, 2022, the Company entered into a five year extension of its Sofia, Bulgaria facility. These operating leases have terms expiring through December 2027. Finance Leases The Company has entered into non-cancelable finance leases for certain computer equipment and a vehicle in Clearwater, Florida. During the three months ended June 30, 2022, the Company entered into a 63 month lease for computer equipment. These finance leases have terms expiring through July 2027. Information about the Company’s weighted average remaining lease terms and discount rate assumptions are as follows: June 30, 2022 December 31, 2021 Operating Finance Operating Finance Weighted average remaining lease term (in years) 5.5 3.2 1.0 0.8 Weighted average discount rate 1.83% 3.04% 3.98% 4.00% Maturities of lease liabilities as of June 30, 2022 are as follows: (In thousands) Operating Finance 2022 $ 61 $ 70 2023 119 40 2024 119 21 2025 119 21 2026 119 21 Thereafter 119 12 Total lease payments 656 185 Less imputed interest (32) (7) Present value of lease liabilities 624 178 Less current portion of lease liabilities (110) (85) Long-term portion of lease liabilities $ 514 $ 93

ACCRUED EXPENSES AND OTHER CURR

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	6 Months Ended
	Jun. 30, 2022
Payables and Accruals [Abstract]
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accrued expenses and other current liabilities consisted of the following: (in thousands) June 30, December 31, Accrued payroll $ 621 $ 546 Accrued bonuses 802 2,117 Accrued commissions 1,074 1,656 Accrued product warranties 611 593 Accrued product liability claim insurance deductibles 597 610 Accrued professional fees and legal related contingent liabilities 1,091 421 Joint and several payroll liability 405 1,027 Short-term contract liabilities 821 533 Uncertain tax positions 1,970 1,863 Sales tax payable 143 428 Other accrued expenses and current liabilities 435 493 Total accrued expenses and other current liabilities $ 8,570 $ 10,287 During April 2022, the Company was relieved of approximately $650,000 of its joint and several payroll liability due to the lapse of the statute of limitations on the liability. This adjustment is included in other income, net for the three and six months ended June 30, 2022.

CHINA JOINT VENTURE

CHINA JOINT VENTURE	6 Months Ended
	Jun. 30, 2022
Noncontrolling Interest [Abstract]
CHINA JOINT VENTURE	CHINA JOINT VENTURE In 2019, the Company executed a joint venture agreement with its Chinese supplier (the “China JV”) whereby the Company has a 51% interest. The China JV has been consolidated in these condensed consolidated financial statements. The agreement required the Company to make capital contributions into the newly formed entity of approximately $357,000, which had been fully funded as of December 31, 2021. As of the date of these condensed consolidated financial statements, the China JV has not commenced principal operations. Changes in the Company ’ s investment in the China JV were as follows: Three Months Ended June 30, Six Months Ended (In thousands) 2022 2021 2022 2021 Beginning interest in China JV $ 294 $ 140 $ 317 $ 144 Contributions $ — $ 203 $ — $ 203 Net loss attributable to Apyx $ (25) $ (5) $ (48) $ (9) Ending interest in China JV $ 269 $ 338 $ 269 $ 338

EARNINGS (LOSS) PER SHARE

EARNINGS (LOSS) PER SHARE	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
EARNINGS (LOSS) PER SHARE	EARNINGS (LOSS) PER SHARE Basic earnings (loss) per share (“basic EPS”) is computed by dividing the net income or loss by the weighted average number of common shares outstanding for the reporting period. Diluted earnings (loss) per share (“diluted EPS”) gives effect to all dilutive potential shares outstanding. As the Company is in a net loss position for all periods presented, all potential shares outstanding are anti-dilutive. The following table provides the computation of basic and diluted loss per share. Three Months Ended Six Months Ended (in thousands, except per share data) 2022 2021 2022 2021 Numerator: Net loss attributable to stockholders $ (5,426) $ (4,046) $ (11,371) $ (8,947) Denominator: Weighted average shares outstanding - basic and diluted 34,464 34,321 34,447 34,312 Loss per share: Basic and diluted $ (0.16) $ (0.12) $ (0.33) $ (0.26) Anti-dilutive instruments excluded from diluted loss per common share: Options 6,679 5,561 6,679 5,561

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION Under the Company’s stock option plans, the Board of Directors may grant restricted stock and options to purchase common shares to the Company's employees, officers, directors and consultants. The Company accounts for stock options in accordance with FASB ASC Topic 718, Compensation - Stock Compensation , with stock-based compensation expense recognized over the vesting period based on the fair value on the grant date utilizing the Black-Scholes model, which includes a number of estimates that affect the grant date fair value and the amount of expense to recognize. The Company recognized approximately $1,714,000 and $3,364,000, respectively, in stock-based compensation expense during the three and six months ended June 30, 2022, as compared with $1,369,000 and $2,563,000, respectively, for the three and six months ended June 30, 2021. Stock option activity is summarized as follows: Number of options Weighted average exercise price Outstanding at December 31, 2021 5,397,691 $ 5.95 Granted 1,478,419 10.96 Exercised (119,840) 4.46 Canceled and forfeited (76,997) 9.81 Outstanding at June 30, 2022 6,679,273 $ 7.04 The Company allows stock option holders to exercise stock-based awards by surrendering stock-based awards with an intrinsic value equal to the cumulative exercise price of the stock-based awards being exercised, referred to as net settlements. These surrenders are included in stock options exercised in the options rollforward above. For the three months ended June 30, 2022 and 2021, respectively, we received 14,013 and 6,614 options as payment in the exercise of 19,987 and 4,886 options. For the six months ended June 30, 2022 and 2021, respectively, we received 36,667 and 22,055 options as payment in the exercise of 39,000 and 26,027 options. Common shares required to be issued upon the exercise of stock options would be issued from authorized and unissued shares. The Company calculated the grant date fair value of options granted in 2022 (“2022 Grants”) utilizing a Black-Scholes model. 2022 Grants Strike price $10.96 Risk-free rate 1.6% Expected dividend yield — Expected volatility 69.6% Expected term (in years) 6

INCOME TAXES

INCOME TAXES	6 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES Income tax expense was approximately $96,000 and $107,000 with effective tax rates of (1.8)% and (2.7)% for the three months ended June 30, 2022 and 2021, respectively. Income tax expense was approximately $166,000 and $173,000 with effective tax rates of (1.5)% and (2.0)% for the six months ended June 30, 2022 and 2021, respectively. For the three and six months ended June 30, 2022 and 2021, the effective rates differ from the statutory rate primarily due to the full valuation allowance recorded on the net operating loss (“NOL”) generated during the period, combined with interest and penalties on uncertain tax positions. The Company has gross unrecognized tax benefits of approximately $1,313,000 at June 30, 2022. It recognized accrued interest and penalties related to unrecognized tax benefits in the provision for income taxes in the condensed consolidated financial statements. As of June 30, 2022, the Company had approximately $657,000 in accrued interest and penalties related to unrecognized tax benefits. Included in the income tax expense for the three months ended June 30, 2022 and 2021, respectively, are approximately $53,000 and $51,000 of interest and penalties on the Company's uncertain tax positions. Included in the income tax expense for the six months ended June 30, 2022 and 2021, respectively, are approximately $105,000 and $99,000 of interest and penalties on the Company's uncertain tax positions. If the Company were to prevail on all uncertain tax positions, the resulting impact will be material as the Company will recognize approximately $1,970,000 of income tax benefits in the consolidated statement of operations. During June 2022, the Company was notified by the Internal Revenue Service (“IRS”) that it is examining the Company’s 2018, 2019 and 2020 federal income tax returns. The examination is expected to be completed no later than May 2023. It is expected that all of the uncertain tax positions should be resolved with the completion of the IRS examination.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Litigation The medical device industry is characterized by frequent claims and litigation, and the Company may become subject to various claims, lawsuits and proceedings in the ordinary course of our business. Such claims may include claims by current or former employees, distributors and competitors, claims concerning the marketing and promotion of our products and product liability claims. The Company is involved in a number of legal actions relating to the use of our Helium Plasma technology. The outcomes of these legal actions are not within the Company’s control and may not be known for prolonged periods of time. It believes that such claims are adequately covered by insurance; however, in the case of one of the Company’s carriers, the Company is in a dispute regarding the total level of coverage available. Notwithstanding the foregoing, in the opinion of management, the Company has meritorious defenses, and such claims are not expected, individually or in the aggregate, to result in a material, adverse effect on its financial condition, results of operations and cash flows. However, in the event that damages exceed the aggregate coverage limits of the Company’s policies or if its insurance carriers disclaim coverage, management believes it is possible that costs associated with these claims could have a material adverse impact on the consolidated financial condition, results of operations and cash flows. During December 2021, the Company provided notice of contract termination to an international distributor of the Company. In March 2022, the Company received a letter from the former distributor citing improper contract termination and alleging damages. While the matter is still in the early stages, management has determined that a loss is probable and that a range of estimated losses is approximately $250,000 to $1,000,000. The Company has recorded an estimated loss of $250,000 in professional services in the accompanying Condensed Consolidated Statement of Operations for the six months ended June 30, 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses. In addition, as previously disclosed with the U.S. Securities and Exchange Commission on the Company’s Current Report on Form 8-K filed June 7, 2022, on June 6, 2022, a complaint (the “Complaint”) was filed in the United States District Court for the Middle District of Florida by plaintiff William E. Hattaway, individually and on behalf of all others similarly situated against the Company, Charles D. Goodwin (“Goodwin”), the Company’s President and Chief Executive Officer and a member of the Company’s Board of Directors, and Tara Semb (“Semb”), the Company’s Chief Financial Officer, Treasurer and Secretary, alleging violations by the Company, Goodwin and Semb of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, primarily related to certain public statements and disclosures concerning the off-label usage of certain of the Company’s Advanced Energy products and the impact such usage would have on the Company’s business, operations and prospects. The Complaint seeks an unspecified amount of damages. Although the ultimate outcome of this matter cannot be determined with certainty, the Company believes that the allegations stated in the Complaint are without merit. The Company, Goodwin and Semb intend to defend themselves vigorously in the suit. In the opinion of management, such claims are adequately covered by insurance, however, in the event that damages exceed the aggregate coverage limits of our policy or if our insurance carriers disclaim coverage, we believe it is possible that costs associated with this claim could have a material adverse impact on our consolidated results of operations, financial position or cash flows. While the matter is still in the early stages, management has determined that a loss is probable and that a range of estimated losses is approximately $475,000 to $2,500,000. The Company has recorded an estimated loss of $475,000 in professional services in the accompanying Condensed Consolidated Statement of Operations for the three and six months ended June 30, 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses. The Company accrues a liability in its consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is recorded. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded, actual results may differ from these estimates. Purchase Commitments At June 30, 2022, the Company had purchase commitments totaling approximately $5.6 million, substantially all of which is expected to be purchased within the next eighteen months.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	6 Months Ended
	Jun. 30, 2022
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	RELATED PARTY TRANSACTIONS Several relatives of Nikolay Shilev, Apyx Bulgaria’s Managing Director, are considered related parties. Teodora Shileva, Mr. Shilev’s spouse, is an employee of the Company working in the accounting department. Antoaneta Dimitrova Shileva-Toromanova, Mr. Shilev’s sister, is the manager of human resources. Svetoslav Shilev, Mr. Shilev’s son, is a quality manager in the quality assurance department. The partner in the Company's China joint venture is also a supplier to the Company. For the three months ended June 30, 2022 and 2021, the Company made purchases from this supplier of approximately $143,000 and $529,000, respectively. For the six months ended June 30, 2022 and 2021, the Company made purchases from this supplier of approximately $370,000 and $646,000, respectively. At June 30, 2022 and December 31, 2021, respectively, the Company owed this supplier approximately $99,000 and $1,000.

GEOGRAPHIC AND SEGMENT INFORMAT

GEOGRAPHIC AND SEGMENT INFORMATION	6 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
GEOGRAPHIC AND SEGMENT INFORMATION	GEOGRAPHIC AND SEGMENT INFORMATION Operating segments are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, the Company also considers the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to its chief operating decision maker for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment, accordingly, the Company has not presented a measure of assets by segment. The Company ’ s reportable segments are disclosed as principally organized and managed as two operating segments: Advanced Energy and OEM. “ Corporate & Other ” includes certain unallocated corporate and administrative costs which were not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred. Summarized financial information with respect to reportable segments is as follows: Three Months Ended June 30, 2022 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 8,364 $ 1,928 $ — $ 10,292 Income (loss) from operations (1,252) 469 (5,193) (5,976) Interest income — — 18 18 Interest expense — — (3) (3) Other income, net — — 607 607 Income tax expense — — 96 96 Three Months Ended June 30, 2021 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 9,978 $ 1,246 $ — $ 11,224 Income (loss) from operations 326 263 (4,632) (4,043) Interest income — — 4 4 Interest expense — — (2) (2) Other income, net — — 97 97 Income tax expense — — 107 107 Six Months Ended June 30, 2022 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 19,178 $ 3,607 $ — $ 22,785 Income (loss) from operations (2,591) 786 (10,042) (11,847) Interest income — — 20 20 Interest expense — — (11) (11) Other income, net — — 586 586 Income tax expense — — 166 166 Six Months Ended June 30, 2021 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 17,638 $ 2,224 $ — $ 19,862 Income (loss) from operations (276) 260 (8,772) (8,788) Interest income — — 7 7 Interest expense — — (6) (6) Other income, net — — 4 4 Income tax expense — — 173 173 International sales represented approximately 22.8% and 32.0% of total revenues for the three and six months ended June 30, 2022, respectively, as compared with approximately 34.2% and 34.8% of total revenues for the three and six months ended June 30, 2021, respectively. Revenue by geographic region, based on the customer's “ship to” location on the invoice, are as follows: Three Months Ended Six Months Ended (In thousands) 2022 2021 2022 2021 Sales by Domestic and International Domestic $ 7,947 $ 7,383 $ 15,495 $ 12,949 International 2,345 3,841 7,290 6,913 Total $ 10,292 $ 11,224 $ 22,785 $ 19,862

BASIS OF PRESENTATION (Policies

BASIS OF PRESENTATION (Policies)	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Reclassifications	Reclassifications We have reclassified certain amounts presented in the prior period to conform to the current period presentation. These reclassifications had no impact on previously reported net loss, retained earnings or net cash used in operating activities for the periods presented.
Recent Accounting Pronouncements	In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments—Credit Losses (Topic 326). The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates , which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently expects to continue to qualify as a Smaller Reporting Company, based upon the current SEC definition, and as a result, will be utilizing the deferred elective date. While we are in the process of determining the effects of the adoption of the standard on the condensed consolidated financial statements, we do not expect the impact to be material. No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.
Inventories	Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon direct labor hours.
Share based compensation	Under the Company’s stock option plans, the Board of Directors may grant restricted stock and options to purchase common shares to the Company's employees, officers, directors and consultants. The Company accounts for stock options in accordance with FASB ASC Topic 718, Compensation - Stock Compensation , with stock-based compensation expense recognized over the vesting period based on the fair value on the grant date utilizing the Black-Scholes model, which includes a number of estimates that affect the grant date fair value and the amount of expense to recognize.

INVENTORIES (Tables)

INVENTORIES (Tables)	6 Months Ended
	Jun. 30, 2022
Inventory Disclosure [Abstract]
Schedule of inventory	Inventories consisted of the following: (In thousands) June 30, December 31, Raw materials $ 4,547 $ 3,603 Work in process 2,192 1,441 Finished goods 3,298 1,997 Gross inventories 10,037 7,041 Less: provision for obsolescence (360) (263) Inventories, net $ 9,677 $ 6,778

LEASES (Tables)

LEASES (Tables)	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Lease Costs	Information about the Company’s weighted average remaining lease terms and discount rate assumptions are as follows: June 30, 2022 December 31, 2021 Operating Finance Operating Finance Weighted average remaining lease term (in years) 5.5 3.2 1.0 0.8 Weighted average discount rate 1.83% 3.04% 3.98% 4.00%
Maturities of Operating Lease Liabilities	Maturities of lease liabilities as of June 30, 2022 are as follows: (In thousands) Operating Finance 2022 $ 61 $ 70 2023 119 40 2024 119 21 2025 119 21 2026 119 21 Thereafter 119 12 Total lease payments 656 185 Less imputed interest (32) (7) Present value of lease liabilities 624 178 Less current portion of lease liabilities (110) (85) Long-term portion of lease liabilities $ 514 $ 93
Maturities of Finance Lease Liabilities	Maturities of lease liabilities as of June 30, 2022 are as follows: (In thousands) Operating Finance 2022 $ 61 $ 70 2023 119 40 2024 119 21 2025 119 21 2026 119 21 Thereafter 119 12 Total lease payments 656 185 Less imputed interest (32) (7) Present value of lease liabilities 624 178 Less current portion of lease liabilities (110) (85) Long-term portion of lease liabilities $ 514 $ 93

ACCRUED EXPENSES AND OTHER CU_2

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)	6 Months Ended
	Jun. 30, 2022
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities	Accrued expenses and other current liabilities consisted of the following: (in thousands) June 30, December 31, Accrued payroll $ 621 $ 546 Accrued bonuses 802 2,117 Accrued commissions 1,074 1,656 Accrued product warranties 611 593 Accrued product liability claim insurance deductibles 597 610 Accrued professional fees and legal related contingent liabilities 1,091 421 Joint and several payroll liability 405 1,027 Short-term contract liabilities 821 533 Uncertain tax positions 1,970 1,863 Sales tax payable 143 428 Other accrued expenses and current liabilities 435 493 Total accrued expenses and other current liabilities $ 8,570 $ 10,287

CHINA JOINT VENTURE (Tables)

CHINA JOINT VENTURE (Tables)	6 Months Ended
	Jun. 30, 2022
Noncontrolling Interest [Abstract]
Schedule of China Joint Venture	Changes in the Company ’ s investment in the China JV were as follows: Three Months Ended June 30, Six Months Ended (In thousands) 2022 2021 2022 2021 Beginning interest in China JV $ 294 $ 140 $ 317 $ 144 Contributions $ — $ 203 $ — $ 203 Net loss attributable to Apyx $ (25) $ (5) $ (48) $ (9) Ending interest in China JV $ 269 $ 338 $ 269 $ 338

EARNINGS (LOSS) PER SHARE (Tabl

EARNINGS (LOSS) PER SHARE (Tables)	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Basic and diluted earnings (loss) per share	The following table provides the computation of basic and diluted loss per share. Three Months Ended Six Months Ended (in thousands, except per share data) 2022 2021 2022 2021 Numerator: Net loss attributable to stockholders $ (5,426) $ (4,046) $ (11,371) $ (8,947) Denominator: Weighted average shares outstanding - basic and diluted 34,464 34,321 34,447 34,312 Loss per share: Basic and diluted $ (0.16) $ (0.12) $ (0.33) $ (0.26) Anti-dilutive instruments excluded from diluted loss per common share: Options 6,679 5,561 6,679 5,561

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Summary of stock options and stock awards	Stock option activity is summarized as follows: Number of options Weighted average exercise price Outstanding at December 31, 2021 5,397,691 $ 5.95 Granted 1,478,419 10.96 Exercised (119,840) 4.46 Canceled and forfeited (76,997) 9.81 Outstanding at June 30, 2022 6,679,273 $ 7.04
Schedule of option fair value assumptions	The Company calculated the grant date fair value of options granted in 2022 (“2022 Grants”) utilizing a Black-Scholes model. 2022 Grants Strike price $10.96 Risk-free rate 1.6% Expected dividend yield — Expected volatility 69.6% Expected term (in years) 6

GEOGRAPHIC AND SEGMENT INFORM_2

GEOGRAPHIC AND SEGMENT INFORMATION (Tables)	6 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
Schedule of reporting information by segment	Summarized financial information with respect to reportable segments is as follows: Three Months Ended June 30, 2022 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 8,364 $ 1,928 $ — $ 10,292 Income (loss) from operations (1,252) 469 (5,193) (5,976) Interest income — — 18 18 Interest expense — — (3) (3) Other income, net — — 607 607 Income tax expense — — 96 96 Three Months Ended June 30, 2021 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 9,978 $ 1,246 $ — $ 11,224 Income (loss) from operations 326 263 (4,632) (4,043) Interest income — — 4 4 Interest expense — — (2) (2) Other income, net — — 97 97 Income tax expense — — 107 107 Six Months Ended June 30, 2022 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 19,178 $ 3,607 $ — $ 22,785 Income (loss) from operations (2,591) 786 (10,042) (11,847) Interest income — — 20 20 Interest expense — — (11) (11) Other income, net — — 586 586 Income tax expense — — 166 166 Six Months Ended June 30, 2021 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 17,638 $ 2,224 $ — $ 19,862 Income (loss) from operations (276) 260 (8,772) (8,788) Interest income — — 7 7 Interest expense — — (6) (6) Other income, net — — 4 4 Income tax expense — — 173 173
Schedule of revenue by geographic area	Revenue by geographic region, based on the customer's “ship to” location on the invoice, are as follows: Three Months Ended Six Months Ended (In thousands) 2022 2021 2022 2021 Sales by Domestic and International Domestic $ 7,947 $ 7,383 $ 15,495 $ 12,949 International 2,345 3,841 7,290 6,913 Total $ 10,292 $ 11,224 $ 22,785 $ 19,862

DISPOSAL OF BUSINESS (Details)

DISPOSAL OF BUSINESS (Details) - USD ($)		3 Months Ended		6 Months Ended
	Aug. 30, 2018	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from the disposition of Core business	$ 97,000,000
Symmetry Surgical Inc. | Electro Surgical Disposables and Accessories, Cauteries and Other Products Supply Agreement
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Asset purchase agreement, term	4 years
Sales		$ 0	$ 2,200,000	$ 600,000	$ 3,600,000
Cost of sales		0	1,800,000	500,000	3,000,000
Operating expenses		100,000	300,000	100,000	$ 600,000
Net other income (loss)		$ 0	$ 100,000	$ (100,000)

INVENTORIES (Details)

INVENTORIES (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 4,547	$ 3,603
Work in process	2,192	1,441
Finished goods	3,298	1,997
Gross inventories	10,037	7,041
Less: provision for obsolescence	(360)	(263)
Inventories, net	$ 9,677	$ 6,778

LEASES - Narrative (Details)

LEASES - Narrative (Details)	Jun. 30, 2022
Leases [Abstract]
Operating lease, extension	5 years
Finance lease, term of contract	63 months

LEASES - Lease Terms and Discou

LEASES - Lease Terms and Discount Rates (Details)	Jun. 30, 2022	Dec. 31, 2021
Operating
Weighted average remaining lease term	5 years 6 months	1 year
Weighted average discount rate	1.83%	3.98%
Finance
Weighted average remaining lease term	3 years 2 months 12 days	9 months 18 days
Weighted average discount rate	3.04%	4%

LEASES - Maturities of Lease Li

LEASES - Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Operating
2022	$ 61
2023	119
2024	119
2025	119
2026	119
Thereafter	119
Total lease payments	656
Less imputed interest	(32)
Present value of lease liabilities	624
Less current portion of lease liabilities	(110)	$ (122)
Long-term portion of lease liabilities	514	0
Finance Lease, Liability, Payment, Due [Abstract]
2022	70
2023	40
2024	21
2025	21
2026	21
Thereafter	12
Total lease payments	185
Less imputed interest	(7)
Present value of lease liabilities	178
Less current portion of lease liabilities	(85)	(165)
Finance Lease, Liability, Noncurrent	$ 93	$ 18

ACCRUED EXPENSES AND OTHER CU_3

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Apr. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Accrued payroll	$ 621		$ 546
Accrued bonuses	802		2,117
Accrued commissions	1,074		1,656
Accrued product warranties	611		593
Accrued product liability claim insurance deductibles	597		610
Accrued professional fees and legal related contingent liabilities	1,091		421
Joint and several payroll liability	405	$ (650)	1,027
Short-term contract liabilities	821		533
Uncertain tax positions	1,970		1,863
Sales tax payable	143		428
Other accrued expenses and current liabilities	435		493
Total accrued expenses and other current liabilities	$ 8,570		$ 10,287

ACCRUED EXPENSES AND OTHER CU_4

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES - Narrative (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Apr. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Joint and several payroll liability	$ (405)	$ 650	$ (1,027)

CHINA JOINT VENTURE - Narrative

CHINA JOINT VENTURE - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2019
Noncontrolling Interest [Line Items]
Contributions from non-controlling interest		$ 195		$ 195
Corporate Joint Venture
Noncontrolling Interest [Line Items]
Required capital contribution					$ 357
Contributions from non-controlling interest	$ 0	$ 203	$ 0	$ 203
Corporate Joint Venture | Chinese Supplier
Noncontrolling Interest [Line Items]
Ownership interest						51%

CHINA JOINT VENTURE - Rollforwa

CHINA JOINT VENTURE - Rollforward of Joint Venture (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Beginning interest in China JV			$ 305
Contributions		$ 195		$ 195
Net loss attributable to Apyx	$ (24)	(5)	(47)	(9)
Ending interest in China JV	258		258
Corporate Joint Venture
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Beginning interest in China JV	294	140	317	144
Contributions	0	203	0	203
Net loss attributable to Apyx	(25)	(5)	(48)	(9)
Ending interest in China JV	$ 269	$ 338	$ 269	$ 338

EARNINGS (LOSS) PER SHARE (Deta

EARNINGS (LOSS) PER SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Earnings Per Share Reconciliation [Abstract]
Net loss attributable to stockholders, basic	$ (5,426)	$ (4,046)	$ (11,371)	$ (8,947)
Net loss attributable to stockholders, diluted	$ (5,426)	$ (4,046)	$ (11,371)	$ (8,947)
Denominator:
Weighted average shares outstanding - basic (in shares)	34,464	34,321	34,447	34,312
Weighted average shares outstanding - diluted (in shares)	34,464	34,321	34,447	34,312
Loss per share:
Basic (in dollars per share)	$ (0.16)	$ (0.12)	$ (0.33)	$ (0.26)
Diluted (in dollars per share)	$ (0.16)	$ (0.12)	$ (0.33)	$ (0.26)
Options
Anti-dilutive instruments excluded from diluted loss per common share:
Anti-dilutive instruments (in shares)	6,679	5,561	6,679	5,561

STOCK-BASED COMPENSATION - Narr

STOCK-BASED COMPENSATION - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-Based Payment Arrangement [Abstract]
Stock based compensation	$ 1,714	$ 1,369	$ 3,364	$ 2,563
Stock swaps equity instruments received (in shares)	14,013	6,614	36,667	22,055
Stock swaps (in shares)	19,987	4,886	39,000	26,027

STOCK-BASED COMPENSATION - Summ

STOCK-BASED COMPENSATION - Summary of Stock Options (Details)	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Number of options
Outstanding, beginning of period (in shares) | shares	5,397,691
Granted (in shares) | shares	1,478,419
Exercised (in shares) | shares	(119,840)
Canceled and forfeited (in shares) | shares	(76,997)
Outstanding, end of period (in shares) | shares	6,679,273
Weighted average exercise price
Outstanding, beginning of period (in dollars per share) | $ / shares	$ 5.95
Granted (in dollars per share) | $ / shares	10.96
Exercised (in dollars per share) | $ / shares	4.46
Canceled and forfeited (in dollars per shares) | $ / shares	9.81
Outstanding, end of period (in dollars per share) | $ / shares	$ 7.04

STOCK-BASED COMPENSATION - Fair

STOCK-BASED COMPENSATION - Fair Value Assumptions (Details)	6 Months Ended
	Jun. 30, 2022 $ / shares
Share-Based Payment Arrangement [Abstract]
Strike price (in dollars per share)	$ 10.96
Risk-free rate	1.60%
Expected dividend yield	0%
Expected volatility	69.60%
Expected term (in years)	6 years

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Income tax expense	$ 96	$ 107	$ 166	$ 173
Effective income tax rate	(1.80%)	(2.70%)	(1.50%)	(2.00%)
Unrecognized tax benefits	$ 1,313		$ 1,313
Accrued interest and penalties	657		657
Interest and penalties included in income tax expense	53	$ 51	105	$ 99
Uncertain tax positions that would impact effective tax rate	$ 1,970		$ 1,970

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - Narrative (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Mar. 31, 2022
Loss Contingencies [Line Items]
Purchase obligation	$ 5,600
Contract with International Distributor
Loss Contingencies [Line Items]
Costs accrued	250
Suit Against Goodwin and Simb
Loss Contingencies [Line Items]
Costs accrued	475
Minimum | Contract with International Distributor
Loss Contingencies [Line Items]
Loss Contingency, Estimate of Possible Loss		$ 250
Minimum | Suit Against Goodwin and Simb
Loss Contingencies [Line Items]
Loss Contingency, Estimate of Possible Loss	475
Maximum | Contract with International Distributor
Loss Contingencies [Line Items]
Loss Contingency, Estimate of Possible Loss		$ 1,000
Maximum | Suit Against Goodwin and Simb
Loss Contingencies [Line Items]
Loss Contingency, Estimate of Possible Loss	$ 2,500

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - Co-venturer - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Related Party Transaction [Line Items]
Purchases from related party	$ 143	$ 529	$ 370	$ 646
Due to related parties	$ 99		$ 99		$ 1

GEOGRAPHIC AND SEGMENT INFORM_3

GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details) - segment	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Segment Reporting [Abstract]
Number of reportable segments			2
Number of operating segments			2
International sales, percent of total revenue	22.80%	34.20%	32%	34.80%

GEOGRAPHIC AND SEGMENT INFORM_4

GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Segment Reporting Information [Line Items]
Sales	$ 10,292	$ 11,224	$ 22,785	$ 19,862
Income (loss) from operations	(5,976)	(4,043)	(11,847)	(8,788)
Interest income	18	4	20	7
Interest expense	(3)	(2)	(11)	(6)
Other income (loss), net	607	97	586	4
Income tax (benefit) expense	96	107	166	173
Operating Segments | Advanced Energy
Segment Reporting Information [Line Items]
Sales	8,364	9,978	19,178	17,638
Income (loss) from operations	(1,252)	326	(2,591)	(276)
Interest income	0	0	0	0
Interest expense	0	0	0	0
Other income (loss), net	0	0	0	0
Income tax (benefit) expense	0	0	0	0
Operating Segments | OEM
Segment Reporting Information [Line Items]
Sales	1,928	1,246	3,607	2,224
Income (loss) from operations	469	263	786	260
Interest income	0	0	0	0
Interest expense	0	0	0	0
Other income (loss), net	0	0	0	0
Income tax (benefit) expense	0	0	0	0
Corporate & Other
Segment Reporting Information [Line Items]
Sales	0	0	0	0
Income (loss) from operations	(5,193)	(4,632)	(10,042)	(8,772)
Interest income	18	4	20	7
Interest expense	(3)	(2)	(11)	(6)
Other income (loss), net	607	97	586	4
Income tax (benefit) expense	$ 96	$ 107	$ 166	$ 173

GEOGRAPHIC AND SEGMENT INFORM_5

GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Segment Reporting Information [Line Items]
Sales	$ 10,292	$ 11,224	$ 22,785	$ 19,862
Domestic
Segment Reporting Information [Line Items]
Sales	7,947	7,383	15,495	12,949
International
Segment Reporting Information [Line Items]
Sales	$ 2,345	$ 3,841	$ 7,290	$ 6,913